GEN Exclusives

More »

GEN News Highlights

More »
Feb 21, 2012

Sigma Life Science Gains Rights to iPSC Technology from iPS Academia Japan

  • Sigma Life Science obtained a worldwide license to Kyoto University’s induced pluripotent stem cell (iPSC) patent portfolio in return for a license fee paid to iPS Academia Japan (iPS AJ). The Sigma-Aldrich biological product and services business is already exploiting a zinc finger protein platform and stem cell technology portfolio.

    The company says the licensed technology will enable it to develop new tools for drug discovery and preclinical research, including iPSCs, iPSC-derived primary cells, assays, custom cell lines, and ADME/Tox services.

    “Researchers currently use primary cells derived from techniques that lack consistency and the ability to genetically engineer cells,” states David Smoller, Ph.D., Sigma-Aldrich CSO. “Using the Kyoto IPSC technology and our zinc finger protein technologies, we hope to generate stable, defined sets of cells and subsequently derived tissues whose predictive power will allow us to develop a new paradigm in assay development.”

    iPS Academia Japan was established in  2008 to act as the technology transfer arm for the iPSC platform developed by researchers at Kyoto University. The company is responsible for commercializing the technology and granting licenses to the IP for applications in pharmaceutical research, drug discovery, and healthcare. iPS AJ also provides researchers with human iPSCs to support R&D related to iPSC technology. Existing licensees of the IP include ATCC, AxioGenesis, Cellectis, Cellular Dynamics, Ipierian, ReproCell, DNAVec, Takara, and Univercell.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?